• Age ≥ 18 years old, male or female;

• Phase I trials select pathologically confirmed recurrent central nervous system tumors (including but not limited to anaplastic astrocytoma, anaplastic oligoastrocytoma, glioblastoma, gliosarcoma, anaplastic ependymoma, Medulloblastoma, malignant meningioma, melanoma, etc.) postoperative patients; Phase IIa trial selects postoperative patients with pathologically confirmed recurrent glioblastoma

• KPS score ≥60;

• Partial or complete tumor resection, Ommaya reservoir has been placed in the operation area, and drug administration conditions are available;

• As assessed by the investigator, the site of injection of the trial drug is expected to be in the supratentorial area;

• Life expectancy ≥3 months;

• Blood routine: WBC≥ 3.0×10\^9/L, ANC≥1.5×10\^9/L, PLT≥100×10\^9/L, Hb≥9.0 g/dL;

• Liver and kidney function: total bilirubin ≤ 1.5 times the upper limit of the normal value; AST and ALT \< 2.5 times the upper limit of the normal value; serum creatinine ≤1.5 times the upper limit of the normal value, or creatinine clearance ≥50 ml/min (calculated by Cockcroft/Gault formula);

• Coagulation function: INR≤1.5 times the upper limit of the normal value, APTT≤1.5 times the upper limit of the normal value;

⁃ Women of childbearing age had a negative pregnancy test result within 14 days before enrollment. Female subjects and their spouses received effective contraceptives during and within 6 months of treatment;

⁃ The subjects voluntarily participated in this study, signed the informed consent form, had good compliance, and cooperated with the follow-up.